Lactobacillus rhamnosus R0011 Treatment Enhanced Efficacy of Capecitabine against Colon Cancer in Male Balb/c Mice. (30th June 2022)
- Record Type:
- Journal Article
- Title:
- Lactobacillus rhamnosus R0011 Treatment Enhanced Efficacy of Capecitabine against Colon Cancer in Male Balb/c Mice. (30th June 2022)
- Main Title:
- Lactobacillus rhamnosus R0011 Treatment Enhanced Efficacy of Capecitabine against Colon Cancer in Male Balb/c Mice
- Authors:
- Rahimpour, Milad
Ashabi, Ghorbangol
Rahimi, Ahmad Mustafa
Halimi, Shahnaz
Panahi, Mahshid
Alemrajabi, Mahdi
Nabavizadeh, Fatemeh - Abstract:
- Abstract: The microbiome of the intestinal system is well-known as a modulatory factor. Having a balanced status of microbiota could help to prevent diseases, especially cancers related to the gastrointestinal system. We investigated the effects of Lactobacillus rhamnosus ( Lr ) and capecitabine on tumor size and physiologic features, such as bodyweight, liver enzymes, and blood profile, in a subcutaneously induced cancer model using CT-26 murine colon carcinoma cells. We divided 48 male Balb/c inbred mice into six groups. Lr had been orally pre-inoculated to the mice for 14 day consecutively. CT-26 cells were implanted subcutaneously into the mice's flank. Following the injection of cancer cells, Lr was inoculated to the mice three times per week for four weeks. Capecitabine was inoculated in the third week after the induction of cancer. The tumor size was significantly decreased in treated groups in comparison to the cancer group (1174.5 ± 63.8, 1119.2 ± 86.3, and 985.6 ± 48 mm 3 vs. 1674.2 ± 66 mm 3, P < 0.0001). Data showed that Lr and capecitabine enhanced Bax/Bcl-2 ratio and caspase-3 level compared to cancer group ( p < 0.0001). White blood cells (WBCs) were significantly decreased in the capecitabine group compared to probiotic group ( P < 0.05). Measurement of bodyweight, liver enzymes, and interleukin-6 (IL-6) level showed that Lr, in addition to preventive and therapeutic effects, might have protective effects against chemotherapy side effects. Preventing WBCs'Abstract: The microbiome of the intestinal system is well-known as a modulatory factor. Having a balanced status of microbiota could help to prevent diseases, especially cancers related to the gastrointestinal system. We investigated the effects of Lactobacillus rhamnosus ( Lr ) and capecitabine on tumor size and physiologic features, such as bodyweight, liver enzymes, and blood profile, in a subcutaneously induced cancer model using CT-26 murine colon carcinoma cells. We divided 48 male Balb/c inbred mice into six groups. Lr had been orally pre-inoculated to the mice for 14 day consecutively. CT-26 cells were implanted subcutaneously into the mice's flank. Following the injection of cancer cells, Lr was inoculated to the mice three times per week for four weeks. Capecitabine was inoculated in the third week after the induction of cancer. The tumor size was significantly decreased in treated groups in comparison to the cancer group (1174.5 ± 63.8, 1119.2 ± 86.3, and 985.6 ± 48 mm 3 vs. 1674.2 ± 66 mm 3, P < 0.0001). Data showed that Lr and capecitabine enhanced Bax/Bcl-2 ratio and caspase-3 level compared to cancer group ( p < 0.0001). White blood cells (WBCs) were significantly decreased in the capecitabine group compared to probiotic group ( P < 0.05). Measurement of bodyweight, liver enzymes, and interleukin-6 (IL-6) level showed that Lr, in addition to preventive and therapeutic effects, might have protective effects against chemotherapy side effects. Preventing WBCs' reduction, protecting mice from losing weight, induction of apoptosis, and enhancing the serum level of IL-6 indicated that Lr might be associated with better management of colorectal cancer and chemotherapy side effects. … (more)
- Is Part Of:
- Nutrition and cancer. Volume 74:Number 7(2022)
- Journal:
- Nutrition and cancer
- Issue:
- Volume 74:Number 7(2022)
- Issue Display:
- Volume 74, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 74
- Issue:
- 7
- Issue Sort Value:
- 2022-0074-0007-0000
- Page Start:
- 2622
- Page End:
- 2631
- Publication Date:
- 2022-06-30
- Subjects:
- Cancer -- Periodicals
Nutrition -- Periodicals
Cancer
Nutrition
Periodicals
616.9940654 - Journal URLs:
- http://www.tandfonline.com/toc/hnuc20/current ↗
http://www.tandfonline.com/ ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0163-5581;screen=info;ECOIP ↗ - DOI:
- 10.1080/01635581.2021.2014901 ↗
- Languages:
- English
- ISSNs:
- 0163-5581
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6188.045000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22263.xml